Post-Intervention HIV Control Linked to Early In Vivo CD8+ T-Cell Proliferative Response to Rebound (CROI 2024) - Mar 17, 2024 - Abstract #446; Location: Poster hall; P=N/A, P1/2 | "To determine the relevance of this relationship in vivo, we studied early T cell proliferation in response to reactivating virus in two prospective studies with an analytic treatment interruption (ATI).We previously reported a higher-than-expected rate of post-intervention control after a single-arm combination clinical trial (NCT04357821) in which people with treated HIV received a DNA/MVA vaccine regimen, followed by two bNAbs (10-1074, VRC07-523LS) plus a TLR-9 agonist (lefitolimod), then two bNAbs at the time of ATI. To our knowledge, these studies are the first to demonstrate a relationship between the early in vivo CD8+ T cell proliferative response to viral reactivation and HIV control post-ART. The results support continued focus on developing HIV cure strategies that enhance HIV-specific CD8+ T cell proliferative capacity."
Preclinical • Human Immunodeficiency Virus • Infectious Disease • CD8 • IFNG
|
|
Demi A. Sandel; Michael J. Peluso; Michiko Shimoda; Lily Zemelko; Alaa A. Latif; Amelia N. Deitchman; Gina Borgo; Nitasha A. Kumar; Meghann C. Williams; Barbara K. Felber; Gabriela Fragiadakis; Matthew H. Spitzer; Lillian Cohn; Steven G. Deeks; Rachel L. Rutishauser
|